海洋生物医学可能因未能提交关键财务报告而从Nasdaq公司除名。 Ocean Biomedical faces potential Nasdaq delisting for failing to file key financial reports.
以普罗维登斯公司为基础的一家生物制药公司海洋生物医学公司收到Nasdaq的通知,因为该公司没有提交季度报告和年度报告。 Ocean Biomedical, Inc., a Providence-based biopharma company, received a notice from Nasdaq for failing to file its Quarterly Report and yearly report. 这种不遵守情况可能导致从Nasdaq资本市场除名,预计12月16日将作出决定。 This non-compliance could lead to delisting from the Nasdaq Capital Market, with a decision expected on December 16. 该公司的重点是开发肺癌、脑癌、肺纤维化和疟疾的治疗方法。 The company is focused on developing treatments for lung cancer, brain cancer, pulmonary fibrosis, and malaria.